Literature DB >> 20041318

The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study.

N S Bese1, C Umay, S Serdengecti, N Kepil, N Sut, T Altug, A Ober.   

Abstract

There are no data regarding the late toxicity of trastuzumab (T) administration with radiotherapy (RT). In this experimental study, we aimed to asses if concurrent or sequential administration of T has any impact for the development of radiation-induced pulmonary fibrosis in rats. Fifty-four female Wistar-albino rats were divided into 6 groups. First group of rats (Group 1; concurrent T) had irradiation to whole thoracic region concurrently with T. Second group (Group 2: sequential T-RT) received thoracic irradiation, 1 week after T. Third group (Group 3: sequential RT-T) had thoracic irradiation first and they had T injection 1 week after RT. Fourth group (Group 4: T only) had only T application. Fifth group (Group 5: RT) had only RT. The last group (Group 6: sham) of rats were observed without any application. A single dose of 12 Gy was given to both lungs with an anterior field at 2 cm depth. T dose which was equivalent to 6 mg/kg adult dose was calculated for each rat, and injected by the tail vein. As an end point the extent of pulmonary fibrosis for each field was graded on a scale from 0 (normal lung or minimal fibrous thickening) to 4 (total fibrous obliteration of the field) at histopathological examination. The mean value of fibrosis scores were 1.44, 1.77, 1.75 and 1.62 for Group 1, 2, 3 and 5, respectively, without any statistically significant differences among them (P>0.05). The mean value of fibrosis scores for Group 4 and 6 were 0.25 and 0.33, respectively (P>0.05). When the mean value of fibrosis scores of the groups which had RT with or without T, compared with the observation and the T only groups, the difference was significant (P<0.05) (one-way ANOVA and Tukey HSD post hoc tests) As a conclusion: addition of T to thoracic irradiation either sequentially or concomitantly did not increase radiation-induced pulmonary fibrosis in rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20041318     DOI: 10.1007/s12032-009-9395-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 2.  Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study.

Authors:  Mark Pegram; Debbie Ngo
Journal:  Adv Drug Deliv Rev       Date:  2006-05-23       Impact factor: 15.470

3.  Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.

Authors:  Janet K Horton; Jan Halle; Madlyn Ferraro; Lisa Carey; Dominic T Moore; David Ollila; Carolyn I Sartor
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-27       Impact factor: 7.038

4.  The effects of tamoxifen on radiation-induced pulmonary fibrosis in Wistar albino rats: results of an experimental study.

Authors:  Nuran Senel Bese; Cenk Umay; Sukru Yildirim; Sennur Ilvan; Ahmet Dirican; Seda Salar; Tuncay Altug; Ahmet Ober
Journal:  Breast       Date:  2005-08-02       Impact factor: 4.380

5.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study.

Authors:  Y Belkacémi; J Gligorov; M Ozsahin; H Marsiglia; B De Lafontan; H Laharie-Mineur; L Aimard; E-C Antoine; B Cutuli; M Namer; D Azria
Journal:  Ann Oncol       Date:  2008-03-15       Impact factor: 32.976

9.  The pulmonary response to sublethal thoracic irradiation in the rat.

Authors:  H E Ward; L Kemsley; L Davies; M Holecek; N Berend
Journal:  Radiat Res       Date:  1993-10       Impact factor: 2.841

10.  Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.

Authors:  Richard Shaffer; Scott Tyldesley; Martin Rolles; Stephen Chia; Islam Mohamed
Journal:  Radiother Oncol       Date:  2008-10-29       Impact factor: 6.280

View more
  3 in total

1.  Effects of hormonotherapy administered after concurrent radiotherapy and Trastuzumab on pulmonary fibrosis.

Authors:  Y Benderli Cihan; K Deniz; H Mutlu; B Kaplan
Journal:  Hippokratia       Date:  2013-07       Impact factor: 0.471

2.  Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.

Authors:  Guler Yavas; Cagdas Yavas; Hilal Acar; Hatice Toy; Deniz Yuce; Ozlem Ata
Journal:  Support Care Cancer       Date:  2012-09-01       Impact factor: 3.603

3.  The Impact of Everolimus and Radiation Therapy on Pulmonary Fibrosis.

Authors:  Mehmet Fuat Eren; Ayfer Ay Eren; Mutlay Sayan; Birsen Yücel; Şahende Elagöz; Yıldıray Özgüven; Irina Vergalasova; Ahmet Altun; Saadettin Kılıçkap; Vasudev Daliparty; Nuran Beşe
Journal:  Medicina (Kaunas)       Date:  2020-07-13       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.